StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Moderna (MRNA) Stock Plunges as Deutsche Bank Starts at Sell on Valuation, Sees 25% Downside
October 22, 2021 10:16 AM
Deutsche Bank analyst Emmanuel Papadakis initiated the research coverage of Moderna (NASDAQ: MRNA) at Sell with a price target of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Hot New Coverage
New Coverage
Next Articles
Moderna (MRNA) Enters MOU to Supply up to 110M COVID-19 Vaccine Doses to the African Union
October 26, 2021 5:50 AM
CDC Advisory Committee Recommends Booster Shot of Moderna's (MRNA) COVID-19 Vaccine
October 22, 2021 5:40 AM
